Targeted antimicrobial therapy in the microbiome era

Mol Oral Microbiol. 2017 Dec;32(6):446-454. doi: 10.1111/omi.12190. Epub 2017 Aug 1.

Abstract

Even though the oral microbiome is one of the most complex sites on the body it is an excellent model for narrow-spectrum antimicrobial therapy. Current research indicates that disruption of the microbiome leads to a dysbiotic environment allowing for the overgrowth of pathogenic species and the onset of oral diseases. The gram-negative colonizer, Porphyromonas gingivalis has long been considered a key player in the initiation of periodontitis and Streptococcus mutans has been linked to dental caries. With antibiotic research still on the decline, new strategies are greatly needed to combat infectious diseases. By targeting key pathogens, it may be possible to treat oral infections while allowing for the recolonization of the beneficial, healthy flora. In this review, we examine unique strategies to specifically target periodontal pathogens and address what is needed for the success of these approaches in the microbiome era.

Keywords: antibiotic resistance; antibiotics; microbiome; oral health; selective drug target.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • Biofilms / drug effects
  • Dental Caries / microbiology
  • Drug Resistance, Bacterial
  • Dysbiosis / drug therapy*
  • Dysbiosis / microbiology*
  • Homeostasis
  • Humans
  • Microbiota / drug effects*
  • Mouth / drug effects*
  • Mouth / microbiology*
  • Mouth Diseases / drug therapy
  • Mouth Diseases / microbiology
  • Oral Health
  • Periodontitis / drug therapy
  • Periodontitis / microbiology
  • Porphyromonas gingivalis / drug effects
  • Porphyromonas gingivalis / pathogenicity
  • Streptococcus mutans / drug effects
  • Streptococcus mutans / pathogenicity

Substances

  • Anti-Infective Agents